Oncology Unit, IRCCS Foundation Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
Department of Medical and Surgical Sciences, Unit of Medical Oncology and Biomolecular Therapy, University of Foggia, Policlinico Riuniti, Foggia, Italy.
Crit Rev Oncol Hematol. 2023 Dec;192:104157. doi: 10.1016/j.critrevonc.2023.104157. Epub 2023 Oct 18.
Despite remarkable progress in the last decade, metastatic prostate cancer (mPCa) remains incurable. The approval of PARP inhibitors (PARPis) represents a milestone in this field, which definitively enters the era of precision medicine, as mPCa is often enriched for defects of homologous recombination repair genes. PARPis are now used as single agents for patients with metastatic castration-resistant PCa. Moreover, combinations of PARPis plus androgen-receptor targeted agents and immune checkpoint inhibitors, and earlier applications of PARPis in the metastatic hormone-sensitive PCa are under evaluation, representing the possible upcoming applications of these agents. Mechanisms of sensitization and resistance have been only partially elucidated. In our review, we summarize the current clinical evidence regarding PARPis in mPCa and the future directions of these targeted agents.
尽管在过去十年中取得了显著进展，但转移性前列腺癌（mPCa）仍然无法治愈。聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）的批准代表了该领域的一个里程碑，因为 mPCa 通常富含同源重组修复基因缺陷，这一领域正式进入了精准医学时代。PARPi 现在被用作转移性去势抵抗性 PCa 患者的单一药物。此外，PARPi 联合雄激素受体靶向药物和免疫检查点抑制剂的组合，以及 PARPi 在转移性激素敏感性 PCa 中的早期应用正在评估中，这代表了这些药物的潜在未来应用。目前仅部分阐明了这些药物的增敏和耐药机制。在我们的综述中，我们总结了 PARPi 在 mPCa 中的现有临床证据以及这些靶向药物的未来方向。
Zotero 插件